Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Biodexa Pharmaceuticals plc Adr (BDRX)

1 + Investors. Track Smart Money conviction in BDRX. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -6
Streak
2Q ▼
Buyers last Q
0%

Smart Money Signals — BDRX

Based on 1 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds reduced or closed their BDRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🔻

Below peak — only 12% of 2.5Y high

12% of all-time peak
Only 1 funds hold BDRX today versus a peak of 8 funds at 2025 Q4 — just 12% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.
📉

Outflows — 75% fewer funds vs a year ago

fund count last 6Q
3 fewer hedge funds hold BDRX compared to a year ago (-75% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🔴

Heavy selling pressure — only 0% buying

0 buying7 selling
Last quarter: 7 funds sold vs only 0 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.
➡️

Steady new buyers — ~0 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 0 → 4 → 1 → 0. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

100% of holders stayed for 2+ years

100% conviction (2yr+) 0% medium 0% new
1 out of 1 hedge funds have held BDRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
⚠️

Saturation — most institutions already know this story

0 → 0 → 4 → 1 → 0 new funds/Q
New funds entering each quarter: 0 → 4 → 1 → 0. Far fewer institutions are entering now vs. a year ago. When the pool of potential new buyers shrinks this fast, future price support from institutional inflows weakens significantly.
🏛️

Veteran-anchored — 100% veterans vs 0% newcomers

100% veterans 0% 1-2yr 0% new
Entry-cohort mix of 1 holders: 1 (100%) are 2+ year veterans, 0 entered 1–2 years ago, and 0 (0%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 100% AUM from top-100 funds

100% from top-100 AUM funds
1 of 1 holders are among the 100 largest funds by AUM, controlling 100% of total institutional value in BDRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
2.5
out of 10
Low Exit Risk
Exit risk score 2.5/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — BDRX

In 2026 Q2, 0 hedge funds were net buyers of BDRX, while 7 reduced or exited (1 trimmed, 6 sold completely) — a 0% buyer ratio, indicating net institutional distribution. Net selling has persisted for two consecutive quarters. 100% of total institutional value in BDRX is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -6 funds (more exits than new entries). Total institutional holders: 1.

Hedge Fund Ownership: BDRX

How many hedge funds hold BDRX — quarterly history vs. share price
Quarterly hedge fund ownership of BDRX vs. share price

Market Analysis: BDRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: BDRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Biodexa Pharmaceuticals plc Adr (BDRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much BDRX has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 51d ago
BDRX
-47.9%
XLV
+9.7%

BDRX outperformed XLV by -57.6% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 6d ago
BDRX
-8.6%
XLV
+4.0%

Since the filing became public, BDRX outperformed XLV by -12.6% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

0 top-rated funds 0 high-conviction
Consensus
0.0
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: BDRX
1 + Investors

Track Smart Money conviction in BDRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 1 7 -85.71%
13F Shares 3 369K -100.0%
Total Value $8 $228K -100.0%
New Positions 0 1 -1
Increased Positions 0 2 -2
Closed Positions 6 2 +4
Reduced Positions 1 3 -2
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: BDRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

1 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in BDRX. Verified SEC 13F-HR filings.

QUARTER:
Top 1 BDRX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Rhumbline Advisers 0.00% 3
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Biodexa Pharmaceuticals plc Adr (BDRX)

What does the Smart Money Trend signal show for BDRX?

Selling streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds reduced or closed their BDRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for BDRX?

Heavy selling pressure — only 0% buying: Last quarter: 7 funds sold vs only 0 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

What is the fund quality score for BDRX holders?

Elite ownership — 100% AUM from top-100 funds: 1 of 1 holders are among the 100 largest funds by AUM, controlling 100% of total institutional value in BDRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held BDRX?

100% of holders stayed for 2+ years: 1 out of 1 hedge funds have held BDRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Biodexa Pharmaceuticals plc Adr (BDRX) following the 2026 Q2 hedge fund 13F filings?

As of today, BDRX has moved -8.6% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.0% for the XLV sector ETF — an outperformance of -12.6%. Since the quarter end (June 30, 2026), BDRX has gained -47.9% vs +9.7% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →